Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Short Interest Update

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) was the target of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 7,780,000 shares, a growth of 94.5% from the December 31st total of 4,000,000 shares. Currently, 4.2% of the shares of the stock are short sold. Based on an average daily volume of 100,730,000 shares, the days-to-cover ratio is presently 0.1 days.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on Tonix Pharmaceuticals in a report on Sunday. They issued a "hold" rating for the company.

Hedge Funds Weigh In On Tonix Pharmaceuticals

An institutional investor recently bought a new position in Tonix Pharmaceuticals stock. PFG Investments LLC acquired a new stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 218,003 shares of the company's stock, valued at approximately $72,000. PFG Investments LLC owned 0.12% of Tonix Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). 82.26% of the stock is owned by institutional investors.

Tonix Pharmaceuticals Price Performance

Shares of TNXP traded down $0.23 during mid-day trading on Monday, hitting $0.19. 321,908,757 shares of the company traded hands, compared to its average volume of 115,787,703. Tonix Pharmaceuticals has a one year low of $0.12 and a one year high of $12.48. The business has a 50-day moving average of $0.30 and a 200 day moving average of $0.27. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. The stock has a market capitalization of $36.42 million, a price-to-earnings ratio of 0.00 and a beta of 2.07.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The company had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. As a group, equities analysts expect that Tonix Pharmaceuticals will post -17.63 earnings per share for the current fiscal year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.